AIM IP specialist Tekcapital to sell or float all four portfolio companies 'within 2 years'. Watch the full video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 386.00
Bid: 382.00
Ask: 384.50
Change: 22.00 (6.04%)
Spread: 2.50 (0.65%)
Open: 377.00
High: 392.00
Low: 377.00
Yest. Close: 364.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Hutchison Chi-Med begins latest trial of fruquintinib

Fri, 4th Sep 2020 14:13

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, said on Friday that it has initiated 'FRESCO-2' - a phase 3 registration study of 'fruquintinib' for the treatment of patients with metastatic colorectal cancer (CRC) in the US, Europe and Japan.
The AIM-traded firm said the first patient was dosed on 3 September in the US.

It described FRESCO-2 as a randomised, double-blind, placebo-controlled, multicentre trial being conducted in patients with metastatic CRC.

The primary endpoint of the study was overall survival.

It said the large phase 3 trial would be enrolled in about 130 sites in 10 countries.

"The US Food and Drug Administration (FDA) granted fast track designation for the development of fruquintinib for the treatment of patients with metastatic CRC in June," the board said in its statement.

"Clinical data including the completed phase 3 FRESCO study in Chinese patients and this FRESCO-2 global study, if positive, would support a future new drug application for the treatment of patients with advanced metastatic CRC, based on our agreement with the FDA.

"The FRESCO-2 study design was also reviewed and endorsed by the European Medicines Agency (EMA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA)."

At 1409 BST, shares in Hutchison China MediTech were up 0.36% at 509.81p.

More News

TRADING UPDATES: Cordiant deploys IPO funds; Scotgold gets loan

TRADING UPDATES: Cordiant deploys IPO funds; Scotgold gets loan

4 May 21 20:25

TRADING UPDATES: STV looks to summer's football; In The Style sales up

TRADING UPDATES: STV looks to summer's football; In The Style sales up

29 Apr 21 14:34

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

21 Apr 21 16:02

IN BRIEF: Hutchison China gets USD100 million investment from Baring

IN BRIEF: Hutchison China gets USD100 million investment from Baring

8 Apr 21 15:57

IN BRIEF: Hutchison China starts first phase trials for HMPL-306

IN BRIEF: Hutchison China starts first phase trials for HMPL-306

29 Mar 21 20:20

TRADING UPDATES: Arden Partners to return to annual profitability

TRADING UPDATES: Arden Partners to return to annual profitability

24 Mar 21 16:44

TRADING UPDATES: Origin Enterprises loss slims; Amryt issues guidance

TRADING UPDATES: Origin Enterprises loss slims; Amryt issues guidance

4 Mar 21 12:46

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

25 Feb 21 16:19

UK TRADING UPDATE SUMMARY: Science Group To Beat Forecasts For 2020

UK TRADING UPDATE SUMMARY: Science Group To Beat Forecasts For 2020

11 Jan 21 14:51

IN BRIEF: Hutchison China Lands "Milestone" China Drug Green Light

IN BRIEF: Hutchison China Lands "Milestone" China Drug Green Light

30 Dec 20 22:05

Hutchison China Files US FDA Drug Application For Cancer Treatment

Hutchison China Files US FDA Drug Application For Cancer Treatment

29 Dec 20 12:31

IN BRIEF: Hutchison Chi-Med To Issue USD100 Million In Shares To CPP

IN BRIEF: Hutchison Chi-Med To Issue USD100 Million In Shares To CPP

17 Nov 20 19:31

UK TRADING UPDATE SUMMARY: Hutchison China Drug Application Accepted

UK TRADING UPDATE SUMMARY: Hutchison China Drug Application Accepted

17 Sep 20 21:35

Hutchison Chi-Med begins latest trial of fruquintinib

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, said on Friday that it has initiated 'FRESCO-2' - a phase 3 registration study of 'fruquintinib' for the treatment of patients with metastatic colorectal cancer (CRC) in the US, Europe and Japan.

4 Sep 20 14:13

IN BRIEF: Hutchison China Initiates Phase II Trial Of HMPL-453

IN BRIEF: Hutchison China Initiates Phase II Trial Of HMPL-453

3 Sep 20 21:27

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.